FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Cilinski Lynn (Last) (First) (Middle) 9704 MEDICAL CENTER DRIVE (Street) ROCKVILLE MD 20850 (City) (State) (Zip)						Issuer Name and Ticker or Trading Symbol MACROGENICS INC [MGNX] 3. Date of Earliest Transaction (Month/Day/Year) 02/15/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) VP, Controller and Treasurer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D					tion 2A. Deemed Execution Date,		3. Transac Code (Ir 8)	tion	r. 5)		ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Dwnership Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		g., put	its, calls, warrants, o ansaction of of of Derivative (M		Expiration Date of (Month/Day/Year) Un De					8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Coe	de V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Employee stock option (right to buy)	\$4.82	02/15/2023		A		75,000		(1)	0:	2/15/2033	Common Stock	75,000	\$0	75,000)	D		
Restricted Stock Unit	\$0.0 ⁽²⁾	02/15/2023		A		20,000		(3)		(3)	Common Stock	20,000	\$0	20,000)	D		

Explanation of Responses:

- 1. 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month
- 2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
- $3. \ The \ RSUs \ will \ vest \ as \ to \ 33\% \ of \ the \ total \ shares \ one \ year \ after \ the \ date \ of \ grant \ and \ 33\% \ each \ year \ thereafter.$

Remarks:

/s/ Lynn Cilinski, Attorney-in-

Fact

02/17/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.